Clene Posts 70% Revenue Drop in Q2

Clene (NASDAQ:CLNN), a clinical-stage biopharmaceutical company developing treatments for neurodegenerative diseases, released its second-quarter 2025 earnings on August 14, 2025. The most important news from this release centers on the company’s financial challenges and continued progress with its lead drug candidate, CNM-Au8, which is advancing toward key regulatory milestones. Clene reported a net loss per share of $(0.78) (GAAP). Revenue (GAAP) totaled $27,000 and declined from $91,000 (GAAP) in Q2 2024. Despite reductions in research and administrative costs, cash levels dropped to $7.3 million, underlining a narrowing operational runway. Overall, the period showed clinical and regulatory momentum but continued financial strain.Source: Clene. Note: Analyst estimates for the quarter provided by FactSet. Clene develops therapeutics for neurodegenerative diseases like amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS). Its main asset is CNM-Au8, a gold nanocrystal suspension therapy intended to enhance cell energy and fight oxidative stress. This approach is based on the idea that restoring neuronal activity and cellular health can slow the progression of serious neurological diseases.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool